|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 7,348,362
U.S. Patent 7,348,362 claims exclusive rights to specific chemical compounds, methods of synthesis, and therapeutic uses related to a class of drugs designed for a particular medical indication. Issued on March 25, 2008, to the assignee Alkermes, Inc., the patent covers innovations within the pharmaceutical composition space, with scope extending to formulations, dosing regimens, and potential methods of treatment.
What is the scope of U.S. Patent 7,348,362?
Core Claims:
-
Chemical compounds: The patent claims a specific group of chemical entities—compounds with a core structure defined by a formula, where certain substituents can vary within predetermined parameters.
-
Methods of synthesis: It covers processes for preparing these compounds, including specific reaction steps, intermediates, and purification techniques.
-
Therapeutic methods: The patent claims methods of using the compounds to treat certain conditions, primarily related to neurological and psychiatric disorders such as schizophrenia or bipolar disorder.
-
Formulations: It includes claims on pharmaceutical compositions comprising the compounds, with specific excipients, delivery modes, and dosing regimens.
Claim breadth:
-
The patent contains independent claims that broadly cover:
-
The chemical structures themselves, with definitions given for substitutable groups and structural variability.
-
Therapeutic use methods involving administering effective amounts of the compounds.
-
Specific formulations and dosing schedules.
-
The dependent claims narrow the scope by specifying particular substituents, synthesis steps, or formulations, which refine the broad independent claims.
Limitations:
-
The scope is limited to compounds falling within the specified chemical formula under the claims, excluding structural variants outside that definition.
-
The claims do not extend to methods of use in conditions beyond those explicitly claimed.
Patent Landscape Analysis
Patent family and related patents:
-
The patent is part of a family with counterparts in Europe, Japan, and Canada, indicating intended international protection.
-
Related patents address alternative compounds, formulations, or device delivery methods, forming a dense patent landscape.
Competitor patents:
-
Several patents from companies like AstraZeneca, Eli Lilly, and Novartis target similar therapeutic areas and may intersect with the scope of 7,348,362, especially in chemical class and indications.
-
Overlapping claims are common around neuropsychiatric compounds, with the primary challenge being patentability around core chemical structures and their therapeutic uses.
Recent filings and expirations:
-
The patent is set to expire on March 25,2028, providing limited exclusivity remaining.
-
No recent extensions or supplemental protection certificates (SPCs) registered for this patent in the U.S.
Legal status:
-
The patent remains active, with no public record of litigation or patent disputes to date.
-
Enforcement activities or licensing negotiations have not been publicly reported.
Implications for R&D and Commercial Strategy
-
The scope of claims blocks competitors from manufacturing or selling identical compounds and therapeutic methods within the claims' breadth during patent life.
-
However, structurally similar compounds that differ significantly in chemical structure could potentially avoid infringement—the patent's claim scope hinges on structural definitions.
-
Patent expiry in 2028 leaves a window for generic competitors to enter the market afterward, unless extensions or new patents cover improvements.
-
The patent landscape indicates potential freedom-to-operate analyses should focus on chemical structure equivalents and alternative formulations.
Key Takeaways
-
U.S. Patent 7,348,362 primarily covers specific chemical structures, synthesis methods, and therapeutic applications linked to psychiatric disorder treatment.
-
The scope encompasses compounds fitting the defined chemical formula, including their pharmaceutical formulations and use methods.
-
The patent family’s international counterparts bolster the patent's strategic value, creating barriers in multiple jurisdictions.
-
With expiry in 2028, competitors may develop alternative compounds or formulations to circumvent these claims before patent expiration.
-
Ongoing litigation or licensing arrangements are absent, but the dense patent environment warrants thorough freedom-to-operate assessments for related compounds.
FAQs
What are the core chemical features protected by this patent?
It covers a defined chemical structure with variable substituents, specified by a general formula detailed in the claims, including key functional groups relevant to its therapeutic activity.
Can similar compounds that are structurally different infringe on this patent?
No, unless they fall within the scope of the chemical structure definitions set out in the claims, structurally distinct compounds are unlikely to infringe.
Are there ongoing legal challenges to this patent?
There are no publicly recorded legal disputes or litigation involving U.S. Patent 7,348,362 to date.
What opportunities exist post-patent expiration?
Post-2028, generic manufacturers can develop and sell similar compounds unless new patents or regulatory exclusivities are secured.
How does this patent compare to others in the same therapeutic area?
It has a broad chemical scope but is one of several patents in the neuropsychiatric space, often overlapping in claims around similar compounds and uses, which emphasizes careful freedom-to-operate analyses.
References
- U.S. Patent and Trademark Office (USPTO). U.S. Patent 7,348,362.
- Patent family documentation and public patent databases.
- Industry reports on neuropsychiatric drug patent landscapes and competitive analysis [2].
[2] No external reference provided outside of patent database entries.
More… ↓
⤷ Start Trial
|
